drugset / Trial / NCT00142974

Assessment of the Effect of Tegaserod (2 mg Tid and 6 mg Tid) on Dyspeptic Symptoms in Diabetic Patients With Symptoms of Diabetic Gastropathy

NCT00142974

Phase 2 Terminated 120 enrolled Novartis
RandomizedParallel-groupDouble-blind

Summary

This study is being done to evaluate the safety, tolerability and satisfactory relief of tegaserod against dyspeptic symptoms in diabetic patients with symptoms of diabetic gastropathy.

Timeline

Start
2004-05
Primary completion
2005-04
Completion
2005-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Tegaserod Small molecule 2 mg
Subject Tegaserod Small molecule 6 mg

Indications

No indication recorded.